Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUPLA: Injectable Long-acting Antiretrovirals vs Oral Antiretrovirals in PLHIV with Suboptimal Adherence
NCT06507059Phase 3Active, not recruiting
- Sponsor
- Chang Gung Memorial Hospital
- Start
- Jul 2024
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of cabotegravir + rilpivirine in human immunodeficiency virus infection (HIV), sponsored by Chang Gung Memorial Hospital. Started Jul 2024; status: active, not recruiting.
02
Drugs
cabotegravir + rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT06507059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06507059.